High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.


Journal Article

Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m(2) over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m(2) on day 7 and 4.5mg/m(2) on day 14 was not tolerated, but HiDAC followed by GO 9mg/m(2) on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.

Full Text

Cited Authors

  • Stone, RM; Moser, B; Sanford, B; Schulman, P; Kolitz, JE; Allen, S; Stock, W; Galinsky, I; Vij, R; Marcucci, G; Hurd, D; Larson, RA; Cancer and Leukemia Group B,

Published Date

  • March 2011

Published In

Volume / Issue

  • 35 / 3

Start / End Page

  • 329 - 333

PubMed ID

  • 20688393

Pubmed Central ID

  • 20688393

Electronic International Standard Serial Number (EISSN)

  • 1873-5835

International Standard Serial Number (ISSN)

  • 0145-2126

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2010.07.017


  • eng